Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

Marc Hirsh, Allan Lipton, Harold Harvey, Elise Givant, Kenneth Hopper, Gary Jones, Jacob Zeffren, Daniel Levitt

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Twenty-six patients were treated in this phase I study with the combination of interleukin-2 (IL2) administered as a continuous infusion and Interferon alfa-2a (IFNα-2a) administered intramuscularly to patients in an outpatient setting. The maximum-tolerated dose of both agents given as outpatient therapy was 2 × 106 U/m2 days 1 to 5 of IL2 and 9 × 106 U/m2 days 1, 3, and 5 of IFNα-2a for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Fatigue was the treatment-limiting toxicity, and serious clinical or laboratory abnormalities occurred infrequently during this study. Patients with colon cancer metastatic to the liver tolerated treatment worse than patients with other tumors. Twelve of the 15 patients with renal cell cancer were assessable for response determinations. Of these 12 patients, three exhibited complete tumor regression, three have had partial objective regression, and three patients experienced stabilization of rapidly progressive disease. This therapy appears to be well tolerated in an outpatient treatment setting and shows significant activity against advanced renal cell cancer.

Original languageEnglish (US)
Pages (from-to)1657-1663
Number of pages7
JournalJournal of Clinical Oncology
Volume8
Issue number10
DOIs
StatePublished - Jan 1 1990

Fingerprint

Interleukin-2
Outpatients
Neoplasms
Renal Cell Carcinoma
Therapeutics
Interleukin-9
Maximum Tolerated Dose
interferon alfa-2a
Interferon-alpha
Colonic Neoplasms
Fatigue
Liver

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Hirsh, Marc ; Lipton, Allan ; Harvey, Harold ; Givant, Elise ; Hopper, Kenneth ; Jones, Gary ; Zeffren, Jacob ; Levitt, Daniel. / Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. In: Journal of Clinical Oncology. 1990 ; Vol. 8, No. 10. pp. 1657-1663.
@article{391e7a396d5c4d5d998475535d954984,
title = "Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy",
abstract = "Twenty-six patients were treated in this phase I study with the combination of interleukin-2 (IL2) administered as a continuous infusion and Interferon alfa-2a (IFNα-2a) administered intramuscularly to patients in an outpatient setting. The maximum-tolerated dose of both agents given as outpatient therapy was 2 × 106 U/m2 days 1 to 5 of IL2 and 9 × 106 U/m2 days 1, 3, and 5 of IFNα-2a for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Fatigue was the treatment-limiting toxicity, and serious clinical or laboratory abnormalities occurred infrequently during this study. Patients with colon cancer metastatic to the liver tolerated treatment worse than patients with other tumors. Twelve of the 15 patients with renal cell cancer were assessable for response determinations. Of these 12 patients, three exhibited complete tumor regression, three have had partial objective regression, and three patients experienced stabilization of rapidly progressive disease. This therapy appears to be well tolerated in an outpatient treatment setting and shows significant activity against advanced renal cell cancer.",
author = "Marc Hirsh and Allan Lipton and Harold Harvey and Elise Givant and Kenneth Hopper and Gary Jones and Jacob Zeffren and Daniel Levitt",
year = "1990",
month = "1",
day = "1",
doi = "10.1200/JCO.1990.8.10.1657",
language = "English (US)",
volume = "8",
pages = "1657--1663",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy. / Hirsh, Marc; Lipton, Allan; Harvey, Harold; Givant, Elise; Hopper, Kenneth; Jones, Gary; Zeffren, Jacob; Levitt, Daniel.

In: Journal of Clinical Oncology, Vol. 8, No. 10, 01.01.1990, p. 1657-1663.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase I study of interleukin-2 and interferon alfa-2a as outpatient therapy for patients with advanced malignancy

AU - Hirsh, Marc

AU - Lipton, Allan

AU - Harvey, Harold

AU - Givant, Elise

AU - Hopper, Kenneth

AU - Jones, Gary

AU - Zeffren, Jacob

AU - Levitt, Daniel

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Twenty-six patients were treated in this phase I study with the combination of interleukin-2 (IL2) administered as a continuous infusion and Interferon alfa-2a (IFNα-2a) administered intramuscularly to patients in an outpatient setting. The maximum-tolerated dose of both agents given as outpatient therapy was 2 × 106 U/m2 days 1 to 5 of IL2 and 9 × 106 U/m2 days 1, 3, and 5 of IFNα-2a for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Fatigue was the treatment-limiting toxicity, and serious clinical or laboratory abnormalities occurred infrequently during this study. Patients with colon cancer metastatic to the liver tolerated treatment worse than patients with other tumors. Twelve of the 15 patients with renal cell cancer were assessable for response determinations. Of these 12 patients, three exhibited complete tumor regression, three have had partial objective regression, and three patients experienced stabilization of rapidly progressive disease. This therapy appears to be well tolerated in an outpatient treatment setting and shows significant activity against advanced renal cell cancer.

AB - Twenty-six patients were treated in this phase I study with the combination of interleukin-2 (IL2) administered as a continuous infusion and Interferon alfa-2a (IFNα-2a) administered intramuscularly to patients in an outpatient setting. The maximum-tolerated dose of both agents given as outpatient therapy was 2 × 106 U/m2 days 1 to 5 of IL2 and 9 × 106 U/m2 days 1, 3, and 5 of IFNα-2a for 4 consecutive weeks. A 2- to 4-week rest period was permitted after each 4 weeks of treatment. Fatigue was the treatment-limiting toxicity, and serious clinical or laboratory abnormalities occurred infrequently during this study. Patients with colon cancer metastatic to the liver tolerated treatment worse than patients with other tumors. Twelve of the 15 patients with renal cell cancer were assessable for response determinations. Of these 12 patients, three exhibited complete tumor regression, three have had partial objective regression, and three patients experienced stabilization of rapidly progressive disease. This therapy appears to be well tolerated in an outpatient treatment setting and shows significant activity against advanced renal cell cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025149119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025149119&partnerID=8YFLogxK

U2 - 10.1200/JCO.1990.8.10.1657

DO - 10.1200/JCO.1990.8.10.1657

M3 - Article

VL - 8

SP - 1657

EP - 1663

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -